Onchocerciasis - Pipeline Insight, 2024

This “Onchocerciasis - Pipeline Insight, 2024,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Onchocerciasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Onchocerciasis Understanding

Onchocerciasis: Overview

Onchocerciasis, or river blindness, is a neglected tropical disease (NTD) caused by the parasitic worm Onchocerca volvulus. It is transmitted through repeated bites by blackflies of the genus Simulium. The disease is called river blindness because the blackfly that transmits the infection lives and breeds near fast-flowing streams and rivers, mostly near remote rural villages. The infection can result in visual impairment and sometimes blindness. Additionally, onchocerciasis can cause skin disease, including intense itching, rashes, or nodules under the skin. Worldwide onchocerciasis is second only to trachoma as an infectious cause of blindness.

Onchocerciasis - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Onchocerciasis pipeline landscape is provided which includes the disease overview and Onchocerciasis treatment guidelines. The assessment part of the report embraces, in depth Onchocerciasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Onchocerciasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Onchocerciasis R&D. The therapies under development are focused on novel approaches to treat/improve Onchocerciasis.

Onchocerciasis Emerging Drugs Chapters

This segment of the Onchocerciasis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Onchocerciasis Emerging Drugs

Flubentylosin: AbbVie Flubentylosin (formerly ABBV 4083) is an orally available small molecule, being developed by AbbVie. It inhibits the protein synthesis and is currently in Phase II stage of clinical trial evaluation to treatOnchocerciasis.

Emodepside (BAY 44-4400): Bayer Emodepside has been shown to be microfilaricidal, as well as macrofilaricidal, and has a unique mechanism of action relative to all other anthelmintic drugs. The advantage of emodepside over ivermectin is that it targets multiple life cycle stages of filariae, including the adult worms. Oral emodepside, as a macrofilaricidal, for the treatment of onchocerciases and filariasis, is being developed by Bayer Healthcare. Currently, it is in Phase II stage of clinical trial evaluation to treatOnchocerciasis.

Onchocerciasis: Therapeutic Assessment

This segment of the report provides insights about the different Onchocerciasis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Onchocerciasis

There are approx. 3+ key companies which are developing the therapies for Onchocerciasis. The companies which have their Onchocerciasis drug candidates in the most advanced stage, i.e. phase II include, AbbVie.

Phases

This report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Onchocerciasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Onchocerciasis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Onchocerciasis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Onchocerciasis drugs.

Onchocerciasis Report Insights

• Onchocerciasis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Onchocerciasis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Onchocerciasis drugs?
• How many Onchocerciasis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Onchocerciasis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Onchocerciasis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Onchocerciasis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• AbbVie
• Bayer
• Eisai Co Ltd
• Oak Therapeutics

Key Products

• Flubentylosin
• Emodepside (BAY 44-4400)
• AWZ 1066 S

This product will be delivered within 1-3 business days.